App Dealroom

Published September 30, 2026 · Updated October 1, 2026

Jefferies tips three biotech stocks with blockbuster potential worth $15B+ in peak sales

Read the full story at App Dealroom

Delphia Therapeutics' oral psychedelic DT120 has produced three positive Phase III datasets for major depressive disorder and generalized anxiety.